About us

Fabio has held the role of Chief Operating Officer at Innovavector since May 2024.

He joined InnovaVector in 2022, first as Chief Business Officer and bringing to the company the solid experience in advanced therapies gained at MolMed (now AGC Biologics), a pioneer company in gene therapy, as process developer and later as Business Developer.

He also served as Marketing Manager for Biologics at Eli Lilly.

Fabio holds a Master degree in molecular biology from the university of parma and a master in business administration at SDA Bocconi school of management.

Graduate in Medicine and Surgery from the University of Parma, he received additional training in management and leadership.

Riccardo boasts a multi-year professional career in big corporations, covering general management and commercial strategy roles for important pharmaceutical multinationals. His background is also closely linked to the world of advanced therapies, having held top positions of key companies such as Genzyme and MolMed, of which he was CEO from 2015 to 2020 and led the acquisition of the company by the AGC inc.

Riccardo joined InnovaVector in October 2022, holding the role of Chief Executive Officer.

Mariangela holds a Master degree in economics and business administration from the University of Naples, and gets certification as a certified public accountant and auditor accounts.

She brings more than 18 years of experience in the AFC area(Administration, Finance and Control), as an auditor(Pwc), Group Financial Controller and CFO in companies of medium/large size companies.

Mariangela currently holds the position of Head of Administration, Finance& Control in InnovaVector Srl.

Andrea holds a Master’s Degree in Molecular Biology from the University of Milan in 2014 and has been active in the field of advanced therapy since the beginning of his career. Before joining InnovaVector, he was involved in AGC biologics (formerly MolMed) leading the Upstream team for large-scale viral vector production and later gained experience as Sales Development Manager at Cytiva, managing projects and leading crucial negotiations with the largest pharmaceutical companies and refining and integrating commercial, scientific and technical skills.

Andrea has been part of InnovaVector as Business Development Manager since May 2024.

Chiara held MSc degree in medical biotechnology at Università degli studi di Napoli Federico II in 2017 and has been active in advanced therapy field since 2016. She gained salient experience for several years in Reithera, at the beginning as R&D grade AAV Vectors development scientist and then as Quality Control specialist.

Chiara joined InnovaVector in October 2020 as Quality control senior scientist and from 2023 as Quality control manager.

Mariangela holds a Master degree in economics and business administration from the University of Naples, and gets certification as a certified public accountant and auditor accounts.

She brings more than 18 years of experience in the AFC area(Administration, Finance and Control), as an auditor(Pwc), Group Financial Controller and CFO in companies of medium/large size companies.

Mariangela currently holds the position of Head of Administration, Finance& Control in InnovaVector Srl.

Monica Doria has extensive experience in the field of genetic research and extensive technical know-how in the production of viral vectors that has lasted for over twenty years. She currently works as research grade AAV production manager at InnovaVector since 2020.

Previously, from 2002 to 2020, she managed the AAV Vector Core Facility of TIGEM (Telethon Institute of Genetics and Medicine, Pozzuoli, Italy) and developed a production and purification process that allowed the production of thousands of batches of AAV vectors for use in preclinical studies. Previously, after graduating at Federico II University of Naples, she dedicated herself to scientific research studying molecular mechanisms of the action of hormones on neoplastic cells, at the Vanvitelli University of Naples.

Antonio held MSc degree in Pharmaceutical Biotechnology at Università degli studi di Siena and MBA at Bologna Business School.

Before joining InnovaVector in 2021, Antonio covered several positions into multinational companies. From Novartis Vaccines & Diagnostic and GlaxoSmithKline where he gained experiences in Supplier Quality, Aseptic Production and Direct Procurement to Philip Morris International where first in Bologna and then in London he had the chance to increase his know-how into the FCMG industry covering roles of increasing responsibility into the SupplyChain and IM&S Procurement.

Gael has extensive knowledge and experience in the field of the gene and cell therapy, particularly in the development and optimization of full processes (Upstream amd Downstream) for LV and AAV production/purification for clinical trial using adherent and suspension-serum free cell lines.

With a solid scientific career, he has played relevant roles in renowned biotech companies such as Theravectys and Yposkesi where he has managed and coordinated multidisciplinary research projects with international teams.

In 2021 Gael joined InnovaVector and currently he is Head of Process Development and Technology Transfer at InnovaVector.

Carlo is a chemical engineer with long experience in the field of production and quality assurance in manufacturing of AAV virus, injectable liquids (Vaccines) in Aseptic Operations, and of APIs for pharmaceutical and food applications produced by fermentation and/or synthetic pathway in CDMO organizations.

During his professional experience he has held several roles in multinational companies, mainly in the field of Quality & Sterility Assurance, Production Management and implementation of new products from the development to production on an industrial scale.

In 2023 Carlo joined InnovaVector leading the GMP manufacturing unit.

Rito graduated cum laude in Chemical Engineering at the “Federico II” University of Naples after completing his studies collaborating with Plasmon, Kraft-Heinz group, on the fermentation of engineered bacterial strains and then Rito joined UNILEVER within the Italian Global Research Center in Casalpusterlengo (LO) within the CTI team of Hard Suface Cleaners.

In 2011 Rito held firstly Process Engineer in bacterial area and then Reliability site engineer role for Glaxo, Smith & Kline at the Siena-Rosia site (formerly Novartis Vaccines & Diagnostics), gaining knowledge and responsibilities into the Engineering Dept as Reliability Eng Team Coordinator. During this experience he had the opportunity, among other activities, to participate in several AIFA, FDA and other Authorities Audits for the Engineering Department.

Before joining InnovaVector, Rito held a crucial role in Menarini Farmaceutici (IT) as Corporate Engineering Manager following the realization of a Green Field Pharmaceutical Site for vaccine production, coordinating the construction, commissioning and qualification activities.

Since 2020 Rito is part of the InnovaVector team as Engineering and Facility Manager, following the construction, start-up, commissioning and qualification activities of the new Gene Therapy facility in the city of Pozzuoli (NA).